以下文章来源于启阳路4号 ，作者公司研究院 启阳路4号 . 聚焦财经热点事件，通过深度调查寻找财经真相。 近日，"卤制品三巨头大幅关店网友吐槽吃不起"冲上热搜榜首，阅读量超8000万，讨论量1.1 万，"明明是街边小店非要卖出酒店摆盘的价格"、"每次都说拿一点点就够了，一称40块"、"它 明明可以抢，却还给了我一些鸭脖"，话题词下网友诉说起那些年被价格刺客支配的往事。 反映在卤味三巨头的财报里，营收和利润双跌。 根据近期发布的财报，周黑鸭营收24.5亿元，同比下滑10.7%；净利润9820万元，同比下滑 15%；煌上煌营收17.39亿元，同比下滑9.44%；归属净利润4033万元，同比下滑42.86%；绝 味食品，营收62.57亿元，同比下滑13.84%；净利润2.27亿元，同比下滑34.04%。 "月薪过万，啃不起鸭脖"，已经成了打工人的自我调侃。近年几乎每一次财报一发，"鸭脖卖不 动了""年轻人不爱吃鸭脖了"的讨论声就会出现，"卤味三巨头"到底怎么了？ 卤味三巨头到底有多贵？ 根据绝味鸭脖小程序，定位北京，270克鸭脖30元、240克黑鸭翅中25元、150克鸭肠30元、 120克鸭舌50元。根据周黑鸭小程 ...

撰 文 / 牛跟尚 设 计 / 琚 佳 当外界质疑造车新势力创维汽车何以存活下来时，创维创始人、开沃汽车创始人、创维汽车创始人 黄宏生在3月18日的创维汽车15周年小型媒体沟通会上说，商乘并举，开沃商用车能够为创维汽车 输血，他强调"别忘了客车企业这两年都不错，很赚钱"。 正如这位家电大王所说，2024年及2025年一季度，中国客车厂的小日子的确过得不错。 客车十强全面增长 据中国汽车工业协会（简称中汽协）数据显示，2025年一季度全国客车(6米以上大客车)销量为2.5 万辆，同比增长13.5%。 中国客车企业销量前十排名（6米以上大客车）为：宇通客车，销量7611辆，市场占有率30.2%，仍 是一家独大；中通客车，销量2766辆；金旅客车，销量2474辆；厦门金龙，销量2209辆；苏州金 龙，销量2097辆；福田欧辉，销量1586辆；安凯客车，销量1348辆；比亚迪客车，销量1127辆；亚 星客车，销量889辆；中车电动，销量601辆。 一是宇通客车依然是老大，销量46918辆，同比增长28.48%。2024年实现营业收入372.18亿元，同 比增长37.63%；归母净利润41.16亿元，同比增长126.5 ...

412 成就新汽车人 回族 *** D ■ 8+ 82.2 一篇 | (1.7) E E I I 视 野 跨 界 实 战 團 际 / 撰文 / 孟 为 设计 / 师 超 2025年4月1日清晨，伊万·埃斯皮诺萨（（Ivan Espinosa））仍如往常一样，开着自己金属灰色的左舵日产Fairlady Z跑车来到公司，但他的身份已经从过 去的公司首席企划官，转变成了日本第三大车企——日产（Nissan）的首席执行官。 摆在他面前的，是一个已经千疮百孔的公司。 推 为公司筹措活下去的资金、寻找新的商业合作伙伴、提振公司员工的士气、重塑内部机制与流程、加速更新老旧过时的产品线、扭转北美和中国两大核 心市场的颓势、实现公司扭亏为盈、以及应对美国向进口汽车征收25%高额关税的新挑战。 埃斯皮诺萨戏言，大多数首席执行官在职业生涯中通常只应对一两个重大危机，但他却要 "同时应对四五个危机"。 现在，他必须从一个过去人们眼中对技术痴迷的汽车工程师，通过读书（埃斯皮诺萨在接受采访时表示自己正在读《新CEO》一书）和处理一个个棘手 的实际工作，来加速完成自己的角色转型。 尽管作为天性乐观的墨西哥人，埃斯皮诺萨正在积极应对这些挑战 ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $9.6 million, an increase of 10% from $8.7 million in Q4 2023 [20] - Gross profit increased to $5.8 million in Q4 2024, up from $4.8 million in the year-ago quarter, with gross margins improving to 60.1% from 55.3% [21] - Operating loss improved by 68% compared to Q4 2023, adjusted for non-cash impairment charges [12] Business Line Data and Key Metrics Changes - Average net revenue per XTRAC device increased by 11% over the previous quarter and 6% over the prior year [10] - Equipment revenue was $3.8 million in Q4 2024, compared to $3.1 million in Q4 2023, driven by strong capital sales in international markets [20] - Gross domestic revenue billings in Q4 were $4.9 million, marking the third consecutive quarter of sequential increase [13] Market Data and Key Metrics Changes - International sales reached $4.1 million in Q4 2024, up 27% from Q3 2024 and up 41% from Q4 2023, representing the highest level of international sales to date [15] - The installed base of TheraClearX devices in the U.S. increased to 144 by the end of Q4 2024, up from 92 at the end of 2023 [14] Company Strategy and Development Direction - The company is focusing on improving the utilization of its machines by removing underperforming units and assisting higher-performing accounts [10] - The strategy includes enhancing direct-to-consumer advertising and in-clinic processes to drive patient appointments and revenue growth [12][13] - The company aims to stabilize financial performance and drive growth through strategic initiatives laid out at the beginning of 2024 [24] Management's Comments on Operating Environment and Future Outlook - Management noted a strong seasonal effect between Q4 and Q1, with Q1 typically being the weakest quarter [17] - The company is optimistic about continued progress in 2025, supported by its current financial position and strategic goals [22][23] Other Important Information - The company secured preauthorization for over 3,700 patients with acne in partner clinics year-to-date [14] - The cash position as of December 31, 2024, was $8.6 million, which includes $1.3 million of restricted cash [22] Q&A Session Summary Question: Clarification on TheraClearX device numbers - Management confirmed that 108 of the 144 TheraClearX devices are in accounts that are billing insurance [27] Question: Types of practices and geographical presence for TheraClearX - Initial uptake was stronger in the Northeast, primarily among small- to medium-sized groups [32] Question: Strength of international markets - Key international markets include Japan, China, South Korea, and the Middle East, with strong growth driven by technology appreciation and clinical efficacy [36][38] Question: Criteria for identifying underutilized accounts - Management explained that approximately 10% of accounts are churned annually based on performance metrics [49] Question: Determining new clinics for device placement - New accounts are identified based on historical patient treatment numbers and previous relationships with the company [60]

Financial Data and Key Metrics Changes - The company reported a 125% year-over-year increase in adjusted EBITDA, reaching $19.9 million, while gross profit increased by 1,349% to $20.5 million despite a top-line compression of $15.3 million or 7.9% [14][36] - For the fourth quarter, net sales from continuing operations were $40.7 million, slightly down from $41.2 million in the same quarter of 2023, with gross profit increasing to $7.3 million from a loss of $2.1 million [32][33] - The full-year net sales decreased to $177.9 million from $193.2 million in 2023, but gross profit rose significantly to $22.1 million from $1.5 million [36][37] Business Segment Data and Key Metrics Changes - In the tubular products segment, there was a year-over-year sales decline of $12.4 million, but segment-level gross profit increased by approximately $15 million due to cost management and product line optimization [16] - The specialty chemicals segment achieved its highest quarterly adjusted EBITDA since Q2 2022, driven by a 14% increase in gross margin despite moderate top-line compression [19][20] - Branded product sales in the specialty chemicals segment recorded a double-digit year-over-year increase, primarily driven by efforts in the oil and gas market [22] Market Data and Key Metrics Changes - The total addressable market for the specialty chemicals segment is over $9 billion, with a specific focus on branded products that offer faster cycle times and predictable demand [20] - The company noted a stronger order backlog in the tubular segment than it has seen in four years, indicating improving market dynamics [17] Company Strategy and Development Direction - The company plans to maximize the value of its assets in the tubular product segment while investing in profitable growth in the specialty chemicals segment [7][8] - There is a focus on organic growth within existing product portfolios and underutilized capabilities, with a commitment to high-potential strategic initiatives [25][24] - The company has expanded its stock repurchase program, allowing for the acquisition of up to an additional one million shares over the next 24 months [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's foundation and its ability to drive growth while maintaining operational excellence [8][10] - The outlook for top-line growth is more optimistic for the second half of 2025, with expectations of market share gains rather than market-driven growth [44] - Management highlighted the importance of domestic sourcing and supply chain optimization as a competitive advantage [57][58] Other Important Information - The company remains debt-free with $16 million in cash and $47 million available on its revolving credit facility, positioning it well for future investments [39] - A total of 101,263 shares were repurchased for approximately $1 million during the year [40] Q&A Session Summary Question: Where do you see top-line growth starting? - Management indicated that top-line growth is expected more in the second half of 2025, with any uptick likely due to market share gains rather than market recovery [44] Question: What contributed to the growth in cash from Q3 to Q4? - The increase in cash was primarily driven by optimizing idle inventory and improved cash conversion cycles [48][49] Question: Any updates on underutilized assets? - Management confirmed the sale of a smaller warehouse and mentioned ongoing efforts to find a permanent solution for other underutilized assets [52] Question: How is the new cleaning portfolio being accepted? - The reception was positive, with new opportunities being pursued following the launch at a cleaning conference [55] Question: Is there potential for further margin improvement in chemicals? - Management believes there is potential for ongoing margin improvement as branded product sales increase, although significant price increases are not anticipated for 2025 [61] Question: Is the share repurchase plan feasible? - Management stated that the plan provides optionality and is contingent on market conditions and share price [64] Question: Where do you see the company a year from now? - Management emphasized a pivot to growth, focusing on filling underutilized assets with high-value applications [68]

Hillenbrand (HI) Q1 2025 Earnings Call February 06, 2025 08:00 AM ET Company Participants Sam Mynsberge - Director of Investor RelationsKimberly Ryan - President and Chief Executive OfficerRobert VanHimbergen - CFO & Senior VPDaniel Moore - Partner - Director of Research Conference Call Participants Mitchell Moore - Associate Analyst Operator Greetings and welcome to the Hildebrand First Quarter and Full Year twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A quest ...